The project “ERAPIMM” has been granted by ANR for 3 years (Nov 2020 - Nov 2023).
The teams of :
- Pr R. Deprez-Poulain (Coordinator, M2SV U1177 Inserm | Institut Pasteur de Lille | University of Lille),
- Pr P. van Endert (INEM, INSERM U1151–CNRS UMR8253, University of Paris)
- Pr D. Launay (INFINITE U1286 INSERM| University of Lille| Lille Regional Hospital)
collaborate in a project aiming at discovering and developing of ERAP inhibitors as a new approach to treat autoimmune & auto-inflammatory diseases. In particular, the teams will specifically study applications in Type 1 diabetes, Behcet’s disease and Spondyloarthritis.
